Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?
- PMID: 40455440
- DOI: 10.1089/dia.2024.0612
Does the OP5 Automated Insulin Delivery System Close the Gap in Glycemic Control Between White and Black Youth with Type 1 Diabetes?
Abstract
Background: Use of automated insulin delivery (AID) systems improves glycemic control, however, racial and ethnic disparities in glycemic control among youth with type 1 diabetes (T1D) persist. We studied whether the Omnipod 5 (OP5) AID system could close gaps in glycemia between White and Black youth with T1D. Methods: This retrospective longitudinal analysis compared matched pairs of White and Black youth with T1D using OP5 at two pediatric academic centers. In unadjusted and adjusted models, we assessed changes in the gap in time in range (TIR), average continuous glucose monitor (CGM) glucose, and hemoglobin A1c (HbA1c) between White and Black youth from baseline to 9 days and 90 days. Results: Matched pairs (n = 132) of White and Black youth using OP5 (61% female, mean age 11.6 years, 40% publicly insured, median T1D duration 2.9 years, mean HbA1c 8.6%) were included. Within 9 days of OP5 use, the baseline TIR gap of 7.8% points decreased to 3.9% points (P = 0.052), and the average CGM glucose gap of 20.5mg/dL at baseline decreased to 8.0 mg/dL (P = 0.012), demonstrating a reduction in the gap between groups. At 90 days, there was no significant reduction in gap from baseline for TIR (P = 0.35) or CGM glucose (P = 0.09). When adjusting for insurance and baseline insulin delivery method, there was no significant reduction in gaps at either 9 days or 90 days. All youth had decreases in HbA1c. At 90 days, time in automated mode (88% vs. 94%, P < 0.0001) and boluses per day (3.9 vs. 5.3, P < 0.0001) were lower in Black youth. In multivariable analysis, youth transitioning to OP5 from multiple daily injections had the greatest increases in TIR at 9 days (P < 0.001) and at 90 days (P < 0.01). Conclusions: Gaps in TIR and average CGM glucose between White and Black youth narrow with AID use, but do not close completely. Equitable access to AID should be encouraged for all youth, however, differences in AID interaction emphasize the need for additional interventions to overcome social determinants of health that likely explain the inability of diabetes technology to fully close the gaps.
Keywords: automated insulin delivery; barriers; glycemic control; inequities; minority youth; type 1 diabetes.
Similar articles
-
The Type of Patient Training Does Not Impact Outcomes in the First 90 Days of Automated Insulin Delivery Use.Diabetes Technol Ther. 2024 Oct;26(10):773-779. doi: 10.1089/dia.2024.0096. Epub 2024 Jun 7. Diabetes Technol Ther. 2024. PMID: 38805309
-
Retrospective Comparison of Commercially Available Automated Insulin Delivery With Open-Source Automated Insulin Delivery Systems in Type 1 Diabetes.J Diabetes Sci Technol. 2025 Jul;19(4):1060-1067. doi: 10.1177/19322968241230106. Epub 2024 Feb 16. J Diabetes Sci Technol. 2025. PMID: 38366626 Free PMC article.
-
Continuous glucose monitoring systems for type 1 diabetes mellitus.Cochrane Database Syst Rev. 2012 Jan 18;1(1):CD008101. doi: 10.1002/14651858.CD008101.pub2. Cochrane Database Syst Rev. 2012. PMID: 22258980 Free PMC article.
-
The psychosocial outcomes of advanced hybrid closed-loop system in children and adolescents with type 1 diabetes.Eur J Pediatr. 2024 Jul;183(7):3095-3103. doi: 10.1007/s00431-024-05551-1. Epub 2024 Apr 25. Eur J Pediatr. 2024. PMID: 38661816 Free PMC article.
-
Integrated sensor-augmented pump therapy systems [the MiniMed® Paradigm™ Veo system and the Vibe™ and G4® PLATINUM CGM (continuous glucose monitoring) system] for managing blood glucose levels in type 1 diabetes: a systematic review and economic evaluation.Health Technol Assess. 2016 Feb;20(17):v-xxxi, 1-251. doi: 10.3310/hta20170. Health Technol Assess. 2016. PMID: 26933827 Free PMC article.
Cited by
-
A Review of Real-World Evidence About the Use of Automated Insulin Delivery Systems in People With Type 1 Diabetes.Endocr Pract. 2025 Jun 10:S1530-891X(25)00917-6. doi: 10.1016/j.eprac.2025.06.004. Online ahead of print. Endocr Pract. 2025. PMID: 40505729 Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous